Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Assets (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Assets over the past 15 years, most recently at $239.3 million for Q2 2025.

  • Quarterly results put Assets at $239.3 million for Q2 2025, down 5.76% from a year ago — trailing twelve months through May 2025 was $239.3 million (down 5.76% YoY), and the annual figure for FY2025 was $239.3 million, down 5.76%.
  • Assets for Q2 2025 was $239.3 million at Lifecore Biomedical, Inc. \De\, up from $237.7 million in the prior quarter.
  • Over the last five years, Assets for LFCR hit a ceiling of $506.9 million in Q1 2021 and a floor of $236.7 million in Q1 2023.
  • Median Assets over the past 5 years was $254.7 million (2024), compared with a mean of $304.3 million.
  • Biggest five-year swings in Assets: soared 71.0% in 2021 and later plummeted 45.27% in 2022.
  • Lifecore Biomedical, Inc. \De\'s Assets stood at $421.3 million in 2021, then crashed by 34.5% to $276.0 million in 2022, then fell by 10.93% to $245.8 million in 2023, then rose by 3.89% to $255.4 million in 2024, then decreased by 6.28% to $239.3 million in 2025.
  • The last three reported values for Assets were $239.3 million (Q2 2025), $237.7 million (Q1 2025), and $255.4 million (Q4 2024) per Business Quant data.